Background-In vitro studies suggest that phosphorylation of titin reduces myocyte/myofiber stiffness. Titin can be phosphorylated by cGMP-activated protein kinase. Intracellular cGMP production is stimulated by B-type natriuretic peptide (BNP) and degraded by phosphodiesterases, including phosphodiesterase-5A. We hypothesized that a phosphodiesterase-5A inhibitor (sildenafil) alone or in combination with BNP would increase left ventricular diastolic distensibility by phosphorylating titin.
H alf of heart failure (HF) patients have preserved ejection fraction (HFpEF), and age and hypertension are potent risk factors for HFpEF. 1 Although the pathophysiology of HFpEF is complex, reduced left ventricular (LV) diastolic compliance or distensibility is often present in HFpEF and elderly hypertensive patients 2 and may be due to hypertrophy, increased extracellular matrix, or changes in cardiomyocyte function. 2, 3 Transcriptional (isoform distribution) and posttranslational (phosphorylation state) modifications of titin alter its tensile properties and, in turn, passive myofiber stiffness. 4 -9 Titin exists in 2 isoforms, the longer and more compliant isoform N2BA and the shorter, stiffer isoform N2B, both of which contain a common N2-B unique sequence (N2-Bus). Phosphorylation of the N2-Bus by cAMP-and cGMP-dependent protein kinases (PKA and PKG, respectively) decreases passive tension in skinned cardiac strips and isolated cardiomyocytes in vitro. 4 -7,9 PKG-mediated reductions in passive tension were linked to phosphorylation and increased the compliance of the N2-Bus region of titin. 6 Furthermore, hypophosphorylation of titin in myocardium harvested from humans with dilated cardiomyopathy has been reported. 6 Thus, titin hypophosphorylation may contribute to diastolic dysfunction in HF, and cGMP-activating therapies may phosphorylate titin and improve diastolic function.
Clinical Perspective on p 2891
Nitric oxide (NO) activates soluble guanylyl cyclase and natriuretic peptides activate particulate guanylyl cyclase to produce cGMP. 10 cGMP signaling is terminated by cGMPhydrolyzing phosphodiesterase (PDE) enzymes. 10 PDE-5A, which is inhibited by sildenafil, selectively hydrolyzes cGMP. The potential for cGMP-activating therapies to modulate diastolic function in vivo is also supported by earlier studies in variable patient populations in which agents that increase myocardial NO resulted in downward shifts in the end-diastolic pressure (EDP)-volume (EDV) relationship (EDPVR; increased distensibility) represented by increases in EDV at matched EDP (increased capacitance). [11] [12] [13] However, in these elegant human studies, concomitant effects on load or extrinsic forces were difficult to exclude, and myofilament protein phosphorylation was not investigated.
We hypothesized that agents that increase cGMP may enhance titin compliance by phosphorylation, leading to improved LV diastolic stiffness or distensibility in vivo. Thus, we tested the effect of a PDE-5A inhibitor (sildenafil) alone or in combination with a natriuretic peptide (B-type natriuretic peptide [BNP]) on LV diastolic function in elderly canines with experimental hypertension (OH dogs) and normal young adult canines (YN dogs). Furthermore, we defined associated alterations in phosphorylation of titin and other sarcomeric proteins.
Methods

Study Design
The study included 11 YN and 15 OH dogs. All experimental procedures were designed in accordance with National Institutes of Health guidelines and approved by the Mayo Institutional Animal Care and Use Committee. Dogs were euthanized by intravenous potassium chloride under deep anesthesia, consistent with guidelines of the Panel on Euthanasia of the American Veterinary Medical Association.
Animal Model
Elderly (age, Ϸ8 -13 years) mongrel dogs were made hypertensive (OH) by bilateral renal wrapping with implantation of an aortic catheter for blood pressure measurement as previously described. 14 YN (age Ϸ1 year) dogs underwent sham surgery and aortic catheter placement. YN dogs were used as controls to determine whether any actions of sildenafil and BNP as putative PKG activators are blunted or heightened in conditions associated with the HFpEF phenotype (age and hypertensive remodeling). All dogs underwent echocardiography in the conscious state before and 8 weeks after surgery.
Hemodynamic Study
Short-term hemodynamic studies were performed in 4 YN and 8 OH dogs 8 weeks after renal wrapping or sham surgery. Animals were anesthetized (fentanyl 0.25 mg/kg followed by 0.18 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 and midazolam 0.75 mg/kg followed by 0.59 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 ), intubated, ventilated, and given maintenance saline infusion (3 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Thoracotomy and pericardiotomy were performed. Under fluoroscopic guidance, animals were instrumented with an ECG, a pulmonary artery catheter, an LV integrated pressure-conductance catheter (Millar), a left atrial and central aortic high-fidelity pressure transducer (Millar), a pneumatic occluding device around the thoracic inferior vena cava, and an atrial lead for pacing at 10 to 20 bpm above sinus rate. The conductance catheter was calibrated with the measurement of blood conductance (), thermodilution stroke volume, and parallel conductance (hypertonic saline method) as previously described. 14 All dogs received autonomic blockade with atropine (1 mg) and propranolol (2 mg/kg). Steady-state and inferior vena cava occlusion (in triplicate) data were collected at suspended end expiration at baseline (after autonomic blockade). Sildenafil (2 mg/kg intravenous bolus) was then administered and data collection was repeated 30 minutes later. Next, BNP was administered (2-g/kg bolus and 0.01-g ⅐ kg Ϫ1 ⅐ min Ϫ1 infu-sion) with data collection 30 minutes later. Blood for plasma cAMP and cGMP concentrations by radioimmunoassay was collected at each experimental period. After each stage of drug treatment, hemodynamic data collection or plasma/tissue biopsy specimen collection was completed in 5 to 10 minutes; then the next treatment was started.
Pressure-Volume Analysis
Data were collected and analyzed with Sonoview and Cardiosoft software (Sonometrics Corp). The end-systolic pressure (ESP)-volume (ESV) relationship (ESPVR) was defined as ESPϭEes(ESV-V 0 ), where Ees (end-systolic elastance) is the slope of ESPVR and V 0 is its volume axis intercept. The EDPVR data points were fit to the monoexponential equation EDPϭ␣e ␤ϫEDV using least-squares nonlinear regression. 15 To assess LV diastolic distensibility independently of load/extrinsic pericardium-mediated forces, the EDV at a common EDP on the sequential EDPVRs was measured (LV diastolic capacitance) with the EDP midway down the baseline EDPVR used as the comparator ( Figure  1 ). Similarly, we measured systolic capacitance on the sequential ESPVRs measuring ESV at a common ESP defined at the midpoint of the baseline ESPVR.
Ventricular Biopsy and Biochemical and Mechanical Measurements
Although sarcomeric protein phosphorylation status may display transmural variation, 16 we assessed average phosphorylation on full-thickness LV biopsies. Because the biopsy and hemostatic sutures would alter chamber diastolic properties, serial samples were harvested from different regions of the anterior or anterior lateral wall from 7 YN and 7 OH dogs subjected to an identical experimental protocol without collection of hemodynamic data. Biopsy samples were frozen in liquid nitrogen within seconds and stored at Ϫ80°C until use. Protein phosphorylation states were analyzed by 1-dimensional and, in a subset of dogs, 2-dimensional SDS-PAGE with Western blotting, phosphoprotein staining, or autoradiography as previously described. 4, 6, 17 Passive force measurements were performed in mechanically isolated, skinned, single cardiomyocytes as described previously. 4 Single cardiomyocytes (2-5 per dog) from 3 OH and 3 YN dogs obtained at baseline and after each serial treatment were attached between a force transducer and a motor. Their sarcomere length was adjusted to 2.2 m, and passive force (F passive ) was measured in relaxing buffer. See the online-only Data Supplement for details.
Statistics
All continuous variables are presented as meanϮSD. The Student t test was used to compare echocardiographic characteristics between OH and YN dogs at baseline and to assess change (paired t test) from baseline to 8 weeks after surgery. Two-way ANOVA with repeated measures was used to test for significant changes during serial treatment and to determine whether changes with sildenafil and BNP differed between YN and OH dogs. Normal distribution is difficult to confirm in the relatively small experimental groups used in these types of translational studies. Thus, data are also reported as median (25th and 75th percentiles), and significance of changes across and between experimental periods was confirmed by the Friedman test, followed by Wilcoxon signed-rank test for individual group comparisons (Tables I and II in the online-only Data Supplement). To test for interaction between serial treatment and OH versus YN status with a nonparametric method, we performed the Scheirer-Ray-Hare extension of the Kruskal-Wallis test. 18 Relationships between variables were tested with the Spearman rank correlation. Statistical significance was set at PϽ0.05 without adjustment for multiple comparisons. Statistical analyses use SPSS (version 19.0, SPSS Inc, Chicago, IL).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Before surgery, OH dogs had similar body weight and EF but higher LV mass and LV/body weight ratio than YN dogs ( Table 1 and Table I in the online-only Data Supplement). At 8 weeks after surgery, systolic, diastolic, mean, and pulse pressures were higher in OH than in YN dogs. Furthermore, LV mass had increased by Ϸ25% in OH but remained stable in YN dogs. There was no significant change in EF in either group.
Effects of Sildenafil and BNP on Ventricular Function
Plasma cAMP and cGMP levels were similar in OH and YN dogs at baseline. Plasma cAMP did not change significantly with sildenafil or BNP treatment ( Table 2 and Table II in the online-only Data Supplement). Plasma cGMP levels increased serially in both OH and YN dogs during treatment with sildenafil and BNP.
In all dogs, diastolic capacitance increased with sildenafil and increased further with BNP but did so similarly (Pϭ0.37 for interaction) in OH and YN dogs (Figures 1 and 2, Table 2 , and Table II in the online-only Data Supplement). Representative EDPVRs in Figure 1 show all data points from the triplicate inferior vena cava occlusions during each experimental period. There was a rightward shift in the EDPVR without consistent changes in the shape of the curve (no statistically significant change in ␤ and ␣), indicative of an increase in distensibility.
The change in diastolic distensibility occurred in the setting of decreases in steady-state arterial and LV systolic pressure, which were higher in OH dogs at baseline (LV ESP 116.1Ϯ22.6 versus 95.0Ϯ6.5 mm Hg; PϽ0.05) but decreased with sildenafil and BNP in both groups. As LV ESP decreased and stroke volume increased, afterload (arterial elastance [Ea]) decreased. Despite decreases in afterload, steady-state LV EDV increased (significantly during BNP infusion) without an increase in LV EDP, whereas mean left atrial pressure decreased progressively, consistent with improved intrinsic LV distensibility. Was higher in OH than YN dogs (47Ϯ10 versus 38Ϯ3 ms; PϽ0.05) and did not change overall with sildenafil or after BNP.
In all dogs, systolic capacitance increased with sildenafil and increased further with BNP but did so similarly (Pϭ0.94 for interaction) in OH and YN dogs ( Figures 1 and 2 , Table  2 , and Table II in the online-only Data Supplement). There was a rightward shift in the ESPVR without consistent changes in the slope of the relationship (no change in Ees but an increase in V 0 ). Similarly, the stroke work-EDV relationship (preload-recruitable stroke work) was shifted rightward (increased volume intercept) without a change in slope. However, there was no change in load-dependent indexes of contractility (EF and peak dP/dt). Despite the rightward shift in the ESPVR, the steady-state ESV did not increase as a result of the concomitant decrease in steady-state ESP.
There was no correlation between changes in afterload (Ea) and changes in systolic (Pϭ0.36) and diastolic (Pϭ0.71) capacitance during sequential therapy.
Passive Force of Isolated Skinned Cardiomyocytes
At baseline, F passive was higher in cardiomyocytes isolated from OH dogs than in those from YN dogs ( Figure 3 ). In both OH and YN dogs, F passive was lower in cardiomyocytes obtained from LV tissue after sildenafil and BNP treatment compared with cardiomyocytes obtained from LV tissue at baseline.
Sarcomeric Protein Phosphorylation
In the LV tissue samples obtained after autonomic blockade, serine 23/24 phosphorylation of troponin I (TnI) did not change with treatment, and the proportion of monophosphorylated and diphosphorylated TnI isoelectric variants remained unaltered (Figure 4 ). Troponin T (TnT) was predominantly phosphorylated, but there was no change in phosphorylation status after therapy ( Figure 5 ). Myosin light chain (MLC)-1 was primarily nonphosphorylated and did not change after therapy ( Figure 5 ). MLC-2 was Ϸ40% monophosphorylated but did not change during treatment ( Figure 5 ). There was nearly complete dephosphorylation of the serine 16 site of phospholamban (after autonomic blockade), and this did not change during treatment ( Figure 6 ).
The ratio of phosphorylated N2B and N2BA isoforms (ProQ Diamond stain) to total titin (Sypro Ruby Stain) increased Ϸ100% with sildenafil compared with baseline, and the higher level of phosphorylation was maintained with BNP ( Figure 7A through 7C) . The ratio of the phosphorylated N2B isoform to the phosphorylated N2BA isoform increased with sildenafil and remained elevated after BNP treatment ( Figure 7A and 7C) . To confirm the findings with the ProQ phosphostain, we also performed back-phosphorylation assays in which skinned fibers were either phosphorylated by adding PKG or first dephosphorylated with a phosphatase and then treated with PKG to assess inherent phosphorylation as the difference in the phosphorylation signal between PKG and phosphatase plus PKG ( Figure 7D through 7F) . Inherent phosphorylation was found to be higher with sildenafil and remained elevated after treatment with BNP in the N2B titin isoform ( Figure 7D and 7E) . In contrast, inherent phosphorylation levels remained unaltered in the T2 titin species, which is considered a degraded form containing the A-band region but little of the elastic I-band region ( Figure 7D and 7F). Hence, the effect of sildenafil/BNP on PKG-mediated titin phosphorylation is mainly an effect on I-band titin.
Discussion
Our primary finding is that sildenafil and sildenafil plus BNP increased diastolic and systolic capacitance in association with increases in total titin phosphorylation and decreases in titin-based myocyte passive stiffness. In these autonomically blocked canines, sildenafil or sildenafil plus BNP did not alter phosphorylation of other sarcomeric proteins. These findings confirm and extend previous in vitro studies in which incubation of myocardial preparations with cGMP-PKG increased phosphorylation of titin and reduced passive diastolic myofiber stiffness. These data suggest that therapies elevating cGMP may provide benefit in the short-or long-term treatment of HFpEF. 
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Effect of Sildenafil and BNP on Diastolic Distensibility
Improvement in passive LV diastolic properties may include decreases in diastolic stiffness (decreased ␤, slope of EDPVR) or increased distensibility in which the EDPVR shifts downrightward without changes in shape. In vivo, sildenafil and BNP resulted in acute increases in LV diastolic capacitance unassociated with consistent changes in ␣ or ␤, suggesting an acute effect on LV distensibility. Short-term increases in LV distensibility may be due to release of extrinsic forces, altered extracellular matrix, or changes in the cardiomyocyte. 2,3,14,15,19 -21 Diastolic capacitance was measured in the open-chest state and in the absence of the pericardium during acute preload reduction to diminish the influence of extrinsic forces. cGMP-enhancing therapies have not been shown to acutely alter fibrosis or collagen cross-links. Thus, short-term changes in the posttranslational state of sarcomeric proteins in response to increases in cGMP provide the most likely explanation of the observed effects as discussed below. The enhanced diastolic distensibility associated with cGMP augmentation was associated with increases in steady-state LV EDV without increased steady-state LV EDP and with decreased mean left atrial pressure, all changes consistent with improved diastolic function. The shift indicates that, for a particular LV volume, the LV operates at lower LV pressure, which is reflected in lower left atrial pressure, suggesting potential relief of symptoms and other manifestations of pulmonary congestion.
In these anesthetized, instrumented, open-chest, autonomically blocked canines, EDP was normal at baseline. Thus, we cannot exclude the possibility that changes in the shape of the EDPVR (altered diastolic chamber stiffness constant) would have been evident if data had been collected over a larger range of EDV, providing a more accurate (less extrapolation) characterization of the monoexponential EDPVR. Furthermore, detection of changes in shape of the EDPVR may be obscured by concomitant and reciprocal changes in the stiffness and curvefitting constants. 15 Improvement in diastolic distensibility has similarly been reported during intracoronary nitroprusside, NO, and substance P infusion in humans. [11] [12] [13] Although the presence of the pericardium in these human studies increased the potential for altered right ventricular loading and ventricular interdependence to mediate shifts in the EDPVR, it is notable that our findings (in the absence of the pericardium and with measurements in the midportion of the EDPVR) are similar. In human subjects with dilated cardiomyopathy, N G -monomethyl-L- arginine, an NO synthase inhibitor, impaired diastolic compliance. 22 The present findings with sildenafil and BNP are consistent with these previous studies in which cGMP was increased via NO and soluble guanylyl cyclase.
Effect of Sildenafil and BNP on Systolic Capacitance
Sildenafil and BNP increased systolic capacitance, as exhibited by the rightward shift in the ESPVRs with increased ESV at a common ESP and an increase in the volume axis intercept of the ESPVR (V 0 ) without a change in the slope of the ESPVR (Ees). Similarly, the stroke work-EDV relationship (preload-recruitable stroke work) was shifted rightward without a change in slope. Although these changes are consistent with a negative inotropic effect, more load-dependent indexes of systolic performance (EF, peak dP/dt) did not change with sequential treatment, likely owing to the concomitant decrease in afterload.
It is now well understood that the ESPVR is not linear, that the degree and nature of nonlinearity vary with inotropic state, and that the volume intercept (V 0 ) and slope (Ees) may change with changes in inotropic state (reviewed by Burkhoff et al 15 ). Furthermore, the ESPVR is not truly load independent because the inotropic state varies directly with afterload impedance, an effect attributed to load-dependent changes in actin-myosin interactions and calcium sensitivity of the troponin regulatory complex. 15 Thus, sildenafil-and sildenafil plus BNP-mediated decreases in afterload could contribute to the rightward shift in the ESPVR, 14, 23 although the changes in afterload were subtle (Ϸ10-mm Hg change in ESP) and there was no correlation between change in afterload and changes in systolic capacitance. Although we believe that the decrease in the passive tensile properties of cardiomyocytes after sildenafil and BNP infusion explains the increased systolic capacitance, a contribution of afterload reduction, particularly seen after BNP infusion, cannot be excluded. Some 24, 25 but not all 26, 27 in vivo studies have reported a subtle but detectable negative inotropic effect of cGMPactivating compounds, although subject characteristics, methodology, and experimental conditions in these studies varied and none investigated the combination of PDE-5A inhibition and natriuretic peptides.
Although still controversial, several recent reports have supported a contribution from titin-based passive tension to length-dependent activation (Frank-Starling relationship) in the cardiac sarcomere. 28, 29 However, despite decreased passive tension in isolated cardiomyocytes, we have not detected a clear change in preload-recruitable stroke work or Ees with sildenafil or the addition of BNP.
Mechanism of Sildenafil-and BNP-Mediated Effects on Myocardial Function
cGMP may alter myocardial function via PKG-mediated phosphorylation of sarcomeric or regulatory proteins or by Figure 7 . Phosphorylation of titin. A, Representative phosphoprotein stain (ProQ diamond) and total protein stain (Sypro Ruby) of a titin gel at baseline and after sequential treatment with sildenafil and B-type natriuretic peptide (BNP). B, Group data (nϭ7 per group) for the ratio of phosphorylated titin (ProQ diamond) to total titin (Spyro Ruby) indexed to baseline. C, Group data (nϭ7 per group) for the ratio of the phosphorylated N2B isoform to the N2BA isoform (ProQ diamond). D, Back-phosphorylation assay by autoradiography to assess titin phosphorylation. Skinned fibers were either phosphorylated by adding cGMP-activated protein kinase (PKG) or first dephosphorylated with a phosphatase and then treated with PKG (PPϩPKG) to assess inherent phosphorylation (difference in the phosphorylation signal between PKG and PPϩPKG). The control sample was not treated with PKG. Back-phosphorylation assays were assessed for N2B isoform and T2 degradation product. The signal from the N2BA band on the autoradiograms was too faint to allow a meaningful analysis. E, Group data (nϭ5) for inherent phosphorylation of the N2B isoform. F, Group data (nϭ5) for the inherent phosphorylation of the T2 degradation product. †PϽ0.05 vs baseline. modulating cyclic nucleotide signaling through cGMPstimulated (PDE-2 and -5) or cGMP-inhibited (PDE-3) PDEs. Ex vivo studies of myocytes or multicellular preparations have shown that cGMP stimulators or analogs produce an acceleration of relaxation, an increase in resting cell length, and reduced inotropy and that these effects occur in the absence of changes in calcium transient amplitude or kinetics. 30, 31 Although NO-mediated increases in cGMP blunt the inotropic response to ␤-adrenergic stimulation, 32, 33 the negative inotropic effect of cGMP is PKG-dependent and can occur independently of PKA signaling. 34 The mechanisms whereby PKG alters calcium sensitivity are unclear, although PKG-mediated phosphorylation of TnI has been implicated in in vitro studies. 30, 31, 35 Phospholamban is phosphorylated by PKA and PKG, and modulation of phospholamban phosphorylation alters relaxation and potentially inotropic function, although the circumstances in which PKG-versus PKA-mediated phosphorylation affects phospholamban phosphorylation status in vivo are poorly understood. 36, 37 TnT, MLC-1, and MLC-2 are not known to be phosphorylated by PKG, but this has not been widely studied. Importantly, in our autonomically blocked dogs, neither sildenafil nor sildenafil plus BNP altered the phosphorylation status of TnI, phospholamban, TnT, MLC-1, or MLC-2. Of note, TnI and particularly phospholamban were highly dephosphorylated, likely owing to the presence of autonomic blockade. Consistent with the lack of change in TnI or phospholamban phosphorylation status, there was no consistent effect on the speed of relaxation with sildenafil or sildenafil plus BNP.
Although sildenafil and sildenafil plus BNP had no effect on the regulatory proteins noted above, titin phosphorylation was increased with sildenafil and sildenafil plus BNP with preferential phosphorylation of the springy I-band region. In vitro studies show that passive tension in the physiological range of sarcomere length is critically influenced by titin. 38 Relative expression of the N2BA titin isoform increases in proportion to body size in mammals and allows longer operating sarcomere lengths without increases in passive tension. 39, 40 Phosphorylation of titin by incubation with PKA and PKG acutely decreases passive tension in cardiomyocytes and myofibers in vitro, most dramatically after initial dephosphorylation. 6, 7, 9 Both kinases phosphorylate titin at the N2-Bus segment, and this posttranslational event enhances titin compliance and thus reduces myofiber passive stiffness. 6 We observed that titin phosphorylation did not increase further after BNP was added to sildenafil despite a substantial increase in plasma cGMP. However, the 80% inherent phosphorylation after sildenafil administration, as measured with back-phosphorylation assays, suggests potential saturation.
We used sildenafil, a PDE-5A inhibitor, and BNP to enhance cGMP signaling. Recently, there has been uncertainty regarding the expression of PDE-5A in cardiomyocytes. 41, 42 However, the presence of sildenafil-induced physiological effects in cardiomyocytes is supported by studies demonstrating sildenafil stimulation of cGMP-associated electric currents in isolated rat cardiomyocytes transfected with cGMP-gated ion channels. 43 Sildenafil may also have nonselective inhibitory effects on a different PDE known to be abundantly expressed in the heart, PDE-1. 44, 45 Regardless of the mechanism for cGMP enhancement by sildenafil in the heart, the short-term hemodynamic and titin phosphorylation effects of sildenafil in our experiments are unequivocal.
The ratio of phosphorylated titin to total titin increased after sildenafil therapy with no further increase with BNP treatment. Most changes in titin phosphorylation appeared to occur within the I-band region. Moreover, the ratio of phosphorylated N2B to N2BA titin isoforms increased after sildenafil treatment with no further change after the addition of BNP. Fukuda et al 5 showed that the extent of reduction in passive tension during phosphorylation of titin by PKA is highest in myocardial tissue with more of the N2B isoform. They postulated that passive force reduction is due to a reduction in the ratio of the length of the phosphorylated segment to the length of the titin isoform. Thus, phosphorylation of the shorter N2B isoform will be associated with a larger passive force reduction. Although phosphorylation of the N2-Bus segment is linked to changes in titin elasticity, there are other PKG-sensitive phosphorylation sites on titin. 6 Thus, correlation between overall titin phosphorylation and changes in diastolic function is not likely to be linear.
We measured F passive in isolated skinned cardiomyocytes ex vivo, which was lower after treatment with sildenafil and maintained after the addition of BNP. F passive has a strong correlation with LVEDP and other indexes of diastolic function, including radial myocardial stiffness modulus (E) and circumferential LV end-diastolic wall stress (). 46 Human subjects with diastolic HF have higher F passive compared with normal subjects. 46 Because the cardiomyocytes were treated in a manner that disrupts the sarcolemma and other membranes and with experiments performed in nonactivating (Ca 2ϩ -free) buffer, altered calcium handling is not responsible for the observed changes in F passive . Because we excluded posttranslational changes in myofilament-associated proteins (TnI, TnT, MLC-1, and MLC-2), titin phosphorylation changes are most likely to explain the change in F passive . The lack of improvement in F passive after the addition of BNP to sildenafil despite an increase in plasma cGMP may be secondary to saturation of titin phosphorylation.
The EDPVR represents a summary of the PVR at the end of diastole in each cardiac cycle and is affected by any intervention or physiological process that contributes to active relaxation and passive stiffness properties of the ventricular chamber. Impairment or incomplete relaxation (at higher heart rates) and increased passive diastolic tone will contribute to changes in the EDPVR. Impaired relaxation may be due to posttranslational changes in myofilamentassociated proteins (TnI, TnT, MLC-1, and MLC-2) regulating calcium sensitivity or calcium transients (phospholamban), which were not affected in our experiments with sildenafil or sildenafil plus BNP.
We found a short-term increase in LV distensibility reflected in diastolic LV capacitance and the rightward shift in the EDPVR during treatment with sildenafil that was further enhanced with the addition of BNP. However, titin phosphorylation and cardiomyocyte F passive did not change further after the addition of BNP. There are several potential explanations for the improved diastolic distensibility with BNP other than posttranslational changes in titin. Changes in systemic afterload may influence systolic and diastolic stiffness or distensibility. 22, 32 Ludbrook et al 47 observed a downward shift of the EDPVR with no appreciable alteration in the stiffness constant with a vasodilator (16% decrease in mean arterial pressure) in human HF. Although PDE-5 is thought to be specific for NO-soluble guanylyl cyclase-derived cGMP, 43 pulmonary arterial vasodilation in response to BNP is markedly accentuated in the presence of sildenafil. 48 Thus, despite pericardiotomy, we cannot exclude that an effect of BNP is to reduce ventricular interdependence via effects on right ventricular load. Finally, sildenafil-and BNP-mediated reduction in coronary perfusion pressure may enhance diastolic distensibility. 49 Unfortunately, we did not measure right ventricular or coronary perfusion pressure.
Limitations
The inability to collect myocardial samples and hemodynamics in the same animals limits the ability to correlate changes in phosphorylation with changes in LV function, and differential dose-dependent and time course effects were not explored. The order of infusions was not altered, so we are unable to determine whether BNP alone phosphorylates titin or alters distensibility. Studies were conducted in the presence of autonomic blockade, and this may influence the interaction of PKG-and PKA-mediated phosphorylation. However, the use of ␤-blockers and age-related decrements in adrenergic responsiveness are ubiquitous in HFpEF and hypertension. A study of the effect of alternate particulate or soluble guanylyl cyclase activators alone and in combination with PDE inhibitors would be of interest.
Conclusions
Diastolic dysfunction is thought to contribute to the pathophysiology of HFpEF, but to date, no therapy has been demonstrated to improve diastolic dysfunction, symptoms, or outcomes in HFpEF. In vitro studies suggest dramatic effects of cGMP-PKG titin phosphorylation on diastolic function. We show here for the first time that therapies known to enhance cGMP enhance diastolic distensibility in association with enhanced titin phosphorylation and reduced titin-based passive stiffness in vivo in a clinically relevant large mammalian model. Although evidence of a negative inotropic effect was also apparent, this was subtle and not associated with decreases in EF or cardiac output. These data provide support for ongoing trials of sildenafil in HFpEF (Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure [RELAX] trial; www.clinicaltrials.gov, NCT00763867) and for future investigation of combining sildenafil and natriuretic peptide therapy to treat HFpEF.
